<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04882189</url>
  </required_header>
  <id_info>
    <org_study_id>13803</org_study_id>
    <nct_id>NCT04882189</nct_id>
  </id_info>
  <brief_title>Study of Endothelial Cell Condition After Cataract Surgery Performed Using Capsulorhexis or ZEPTO</brief_title>
  <acronym>ZEPTO</acronym>
  <official_title>A Prospective Randomized Controlled Masked Study of Endothelial Cell Condition After Cataract Surgery Performed Using Manual Capsulorhexis or the ZEPTO Precision Capsulotomy System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centricity Vision, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centricity Vision, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will use images of the subjects' corneal endothelium obtained using non-invasive&#xD;
      specular microscopy to obtain corneal endothelial cell density, the coefficient of variation&#xD;
      in endothelial cell size, and the percentage of hexagonal endothelial cells following routine&#xD;
      cataract surgery performed using the standard method of manual capsulorhexis compared to&#xD;
      cataract surgery performed using Zepto Precision Capsulotomy System.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial Cell Density Loss</measure>
    <time_frame>3 months</time_frame>
    <description>Post Cataract Surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endothelial Cell Density Loss</measure>
    <time_frame>1 month</time_frame>
    <description>Post Cataract Surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coefficient of Variation in Endothelial Cell Size</measure>
    <time_frame>1 and 3 months</time_frame>
    <description>Post Cataract Surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of hexagonal cells</measure>
    <time_frame>1 and 3 months</time_frame>
    <description>Post Cataract Surgery</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Endothelial Cell Density Loss</condition>
  <arm_group>
    <arm_group_label>Capsulorhexis</arm_group_label>
    <description>Capsulotomies conducted by Capsulorhexis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZEPTO Precision Capsulotomy Device</arm_group_label>
    <description>Capsulotomies conducted by ZEPTO Precision Capsulotomy Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Imaging</intervention_name>
    <description>Images of the corneal endothelium will be obtained using specular microscopy at 1- and 3-months post cataract surgery.</description>
    <arm_group_label>Capsulorhexis</arm_group_label>
    <arm_group_label>ZEPTO Precision Capsulotomy Device</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with symptomatic age-related lens cataract desiring lens extraction and IOL&#xD;
        implantation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects consenting to undergoing phacoemulsification and IOL implant surgery for the&#xD;
             treatment of symptomatic age-related lens cataract, and then electing to undergo the&#xD;
             study,&#xD;
&#xD;
          -  Subjects must be willing and able to return for scheduled treatment and follow-up&#xD;
             examinations at 1 and 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-existing corneal endothelium pathology&#xD;
&#xD;
          -  Presence of guttae&#xD;
&#xD;
          -  Narrow angle glaucoma or advanced glaucoma&#xD;
&#xD;
          -  Psuedoexfoliation&#xD;
&#xD;
          -  Zonular abnormalities&#xD;
&#xD;
          -  Corneal endothelial cell density less than 1800 cells/mm2&#xD;
&#xD;
          -  Uveitis&#xD;
&#xD;
          -  Anterior chamber depth less than 2.5mm or greater than 3.75mm&#xD;
&#xD;
          -  Cataract grade LOCS II &gt; 3&#xD;
&#xD;
          -  Posterior polar cataract&#xD;
&#xD;
          -  Planned implantation of IOL &gt; 25D&#xD;
&#xD;
          -  Prior ocular surgery in the study eye&#xD;
&#xD;
          -  History of medications with potential corneal endothelial cell toxicity&#xD;
&#xD;
          -  Any condition that in the surgeon's judgement should exclude the subject from study&#xD;
             enrollment.&#xD;
&#xD;
          -  Current participation in another drug or device clinical study, or participation in&#xD;
             such a clinical study within the prior six months and during the duration of the&#xD;
             current study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Capsule Opacification</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

